BriefMeBro is now free — every edition, no signup. briefmebro.com
BRIEFMEBRO· The 30-second world & markets brief — including the stories they buried.
60FINANCE

Novartis shares fall 9% after multiple drug trial setbacks, including a key cardiovascular drug

⚡ Markets: Direct, significant negative impact on Novartis (NVS) stock. The failure of a late-stage cardiovascular drug also has negative read-through for other companies developing similar treatments.NVS

Swiss pharmaceutical giant Novartis saw its stock price drop sharply after announcing disappointing late-stage trial results for several drugs. The failures included a key cardiovascular treatment and a drug for muscular disease, casting doubt on parts of its development pipeline.

West MSM: noneFinancial press 4Google West 12 countries
5 sources across the spectrum
Financial pressMarketWatch — Why the Dow is being dragged down by a Swiss company’s bad news
Financial pressFinancial Times — Novartis shares sink on latest trial setback
Financial pressFinancial Times — Novartis shares slide after drug for muscular disease fails trial
Financial pressCNBC — Pharma major Novartis falls 9% after three drug trial setbacks
Google WestGoogle News (US) — Cholesterol drug setback casts doubt over multibillion-dollar race
← Full brief